Semaglutide tops dulaglutide when treating patients with type 2 diabetes and CVD Weekly injections of semaglutide are associated with more significant cardiovascular benefits than dulaglutide in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD), according to a new real-world analysis of nearly 60,000 Medicare patients
Theoretically, combining both could leverage dual pathways, but head-to-head combination trials remain absent from the medical literature
Tirzepatide is a once-weekly injection thats FDA-approved for weight loss and chronic weight management under the brand name Zepbound
The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression
In some cases, the sudden onset of the disease, combined with pain, has required therapy with glucocorticoids
His pace is picking up a little bit, she posted after two weeks on the peptide